Experimental achondroplasia drug trial halted early
NCT ID NCT06067425
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called SAR442501 in children with achondroplasia, a common form of dwarfism. The goal was to see if the drug was safe and could improve growth. However, the trial was stopped early after enrolling only 16 children, so we have very little information about how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR442501 (an experimental drug given as a shot under the skin)
What this could lead to
If successful, this drug could help children with achondroplasia grow more, potentially reducing some health complications.
What could go wrong
The trial was terminated early with only 16 participants, so results are very limited. It is unclear if the drug is safe or effective, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0360001
Parkville, Victoria, 3052, Australia
-
Investigational Site Number : 1560001
Wuhan, 430030, China
-
Investigational Site Number : 1560002
Shanghai, 200120, China
-
Investigational Site Number : 3800001
Rome, Roma, 00168, Italy
-
Investigational Site Number : 3800002
Milan, Lombardy, 20122, Italy
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 7240001
Esplugues de Llobregat, Catalunya [Cataluña], 08950, Spain
-
Investigational Site Number : 7240002
Vitoria-Gasteiz, Basque Country, 01008, Spain